LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...

LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ -- Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the Spectra Optia ® Apheresis ...

Terumo's Spectra Optia® Apheresis System Terumo's Spectra Optia® Apheresis System LAKEWOOD, Colo., U.S., and SANTA ROSA, Calif., U.S., July 27, 2022 (GLOBE NEWSWIRE) -- Acute kidney injury (AKI) and ...

In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...

本研究针对细胞采集与单采技术领域的关键问题，通过多国横断面调查揭示了Spectra Optia?单采系统的临床应用趋势。研究人员 ...

LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...

New connectivity captures data at its source, reducing manual burden and enabling broader value across patient care, research and biopharma collaboration FREMONT, Calif., April 21, 2026 ...

New Global Therapy Innovations business unit, led by Veerle d’Haenens, aims to unify therapeutic apheresis and cell and gene therapy expertise to expand therapeutic possibilities Lakewood, CO – 12 ...